491 related articles for article (PubMed ID: 30197477)
1. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
Wang K; Baldwin GS; Nikfarjam M; He H
World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
[TBL] [Abstract][Full Text] [Related]
2. The role of p21-activated kinases in pancreatic cancer.
Yeo D; He H; Baldwin GS; Nikfarjam M
Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
4. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.
Belli S; Pesapane A; Servetto A; Esposito D; Napolitano F; Ascione CM; Allotta A; Zambrano N; Marino FZ; Franco R; Troiani T; Formisano L; Bianco R
Br J Cancer; 2023 Oct; 129(7):1071-1082. PubMed ID: 37568037
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
6. The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma.
Ma Y; Nikfarjam M; He H
Cancer Lett; 2022 Nov; 548():215868. PubMed ID: 36027997
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
Ferro R; Falasca M
World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
[TBL] [Abstract][Full Text] [Related]
8. KRAS as a Therapeutic Target.
McCormick F
Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
[TBL] [Abstract][Full Text] [Related]
9. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
[TBL] [Abstract][Full Text] [Related]
11. Kras
Cheng H; Fan K; Luo G; Fan Z; Yang C; Huang Q; Jin K; Xu J; Yu X; Liu C
Cancer Lett; 2019 Apr; 446():103-111. PubMed ID: 30664964
[TBL] [Abstract][Full Text] [Related]
12. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
13. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
14. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer.
Chu PC; Kulp SK; Bekaii-Saab T; Chen CS
Small GTPases; 2018 Nov; 9(6):452-456. PubMed ID: 27936345
[TBL] [Abstract][Full Text] [Related]
15. Changing the course of pancreatic cancer--Focus on recent translational advances.
Javle M; Golan T; Maitra A
Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
[TBL] [Abstract][Full Text] [Related]
16. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
[TBL] [Abstract][Full Text] [Related]
17. Immune modulatory effects of oncogenic KRAS in cancer.
Hamarsheh S; Groß O; Brummer T; Zeiser R
Nat Commun; 2020 Oct; 11(1):5439. PubMed ID: 33116132
[TBL] [Abstract][Full Text] [Related]
18. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
19. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
